Neurofix Pharma is a Spanish biotech company developing a drug to alleviate the pain suffered by people with spinal cord injuries and improve their quality of life. This drug, NFX88, has already successfully passed phase IIA of its clinical trial and represents a pioneering alternative that seeks to fill the gap in current treatments.

Since its inception in 2015, Neurofix Pharma has received support and recognition from various institutions to promote its project. It is worth highlighting the award of seals such as ‘Best Company NEOTEC line’, ‘Innovative SME’ and ‘EU Horizon 2020 Excellence’, in addition to the support of Enisa, Iberaval, CDTI, ICO and European SME, among others. The progress of NFX88’s clinical trial has allowed Neurofix to be integrated into the Pre-Market Environment (EpM) training programme of the BME (Bolsas y Mercados Españoles), as a step prior to the company’s move into the capital markets. The company also has important investors, including the Matutes family office.

Product under development

NFX88 represents a breakthrough in the treatment of neuropathic pain caused by spinal cord injury. It is a first-in-class drug that stands out for its exceptional safety profile and very promising efficacy results. Because of all these characteristics, NFX88 is positioned as an extremely interesting product with the main objective of significantly improving the quality of life of patients suffering from neuropathic pain.